Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests

  The 66th American Society for Hematology (ASH) Annual Meeting and Exhibition took place from December 7-10, 2023. During the meeting, researchers and other stakeholders shared insights into clinical trends,…

Continue Reading Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests
ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation
source: shutterstock.com

ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation

In the United States, Breakthrough Therapy designation is granted by the U.S. Food and Drug Administration (FDA) to expedite drug development and review. This designation is granted to therapies that…

Continue Reading ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation